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Abstract
Introduction This randomised, open-label, multicentre study
compared the safety and efficacy of an analgesia-based
sedation regime using remifentanil with a conventional hypnotic-
based sedation regime in critically ill patients requiring
prolonged mechanical ventilation for up to 10 days.
Methods One hundred and five randomised patients received
either a remifentanil-based sedation regime (initial dose 6 to 9
µg kg-1 h-1 (0.1 to 0.15 µg kg-1 min-1) titrated to response before
the addition of midazolam for further sedation (n = 57), or a
midazolam-based sedation regime with fentanyl or morphine
added for analgesia (n  = 48). Patients were sedated to an
optimal Sedation–Agitation Scale (SAS) score of 3 or 4 and a
pain intensity (PI) score of 1 or 2.
Results The remifentanil-based sedation regime significantly
reduced the duration of mechanical ventilation by more than 2
days (53.5 hours, P = 0.033), and significantly reduced the time
from the start of the weaning process to extubation by more than
1 day (26.6 hours, P  < 0.001). There was a trend towards
shortening the stay in the intensive care unit (ICU) by 1 day. The
median time of optimal SAS and PI was the same in both
groups. There was a significant difference in the median time to
offset of pharmacodynamic effects when discontinuing study
medication in patients not extubated at 10 days (remifentanil
0.250 hour, comparator 1.167 hours; P  < 0.001). Of the
patients treated with remifentanil, 26% did not receive any
midazolam during the study. In those patients that did receive
midazolam, the use of remifentanil considerably reduced the
total dose of midazolam required. Between days 3 and 10 the
weighted mean infusion rate of remifentanil remained constant
with no evidence of accumulation or of a development of
tolerance to remifentanil. There was no difference between the
groups in SAS or PI score in the 24 hours after stopping the
study medication. Remifentanil was well tolerated.
Conclusion Analgesia-based sedation with remifentanil was
well tolerated; it reduces the duration of mechanical ventilation
and improves the weaning process compared with standard
hypnotic-based sedation regimes in ICU patients requiring long-
term ventilation for up to 10 days.
HR = heart rate; ICU = intensive care unit; MAP = mean arterial pressure; PI = pain intensity; SAS = Sedation–Agitation Scale.Critical Care    Vol 9 No 3    Breen et al.
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Introduction
Most patients who require intensive care need effective anal-
gesia and sedation to control potentially unpleasant symptoms
such as pain and anxiety. Analgesics and sedatives are also
used to allow patients to tolerate nursing procedures and tra-
cheal intubation and to aid in mechanical ventilation. Most
commonly, the combined use of a sedative agent with an opi-
oid is used to achieve this. The sedative agent is titrated
towards the degree of sedation and opioids are added as
judged necessary for pain control.
The pharmacodynamic effects of traditionally used sedative
and opioid drugs are unpredictable and often prolonged in the
critically ill patient for various reasons. The pharmacokinetics
are altered with different volumes of distribution and elimina-
tion half-lives. Multiple drugs are given in large doses for pro-
longed periods, which can lead to drug interactions and
tolerance. There is altered organ function with impaired renal/
hepatic function, altered regional blood flow, protein and
enzyme system dysfunction and altered receptor response. In
addition, the most commonly used sedatives and opioids have
a context-sensitive half-time that increases with time. Thus,
these drugs will accumulate during prolonged use. All opioids
have sedative properties to various degrees at high doses.
However, traditionally the opioid part of a sedation regime is
kept to a minimum to protect against opioid accumulation and
an unpredictable recovery/weaning from mechanical
ventilation.
Remifentanil hydrochloride is a potent, selective µ-opioid
receptor agonist that has a rapid onset of action (about 1 min)
and quickly achieves steady state [1]. Remifentanil is metabo-
lised by non-specific plasma esterases and is therefore inde-
pendent of organ function [2]. Remifentanil is rapidly
metabolised and has a context-sensitive half-time of about 2 to
3 min that is independent of duration of infusion [3]. These fea-
tures of remifentanil make it an ideal agent for use in critically
ill patients. It is easy to titrate and can be given in relatively high
doses for prolonged periods without risk of accumulation [4,5]
or delayed offset of effects [5]. It allows the opioid to be used
as the main drug to provide patient comfort with the sedative
agent being kept to a minimum. Remifentanil as part of an anal-
gesic-based sedative regime (analgo-sedation) has been stud-
ied in critically ill patients for up to 5 days [4-17].
This present study was conducted to assess the efficacy and
safety of a prolonged infusion of remifentanil in critically ill
patients for up to 10 days in comparison with a standard sed-
ative regime of midazolam plus a traditional opioid. The effi-
cacy of remifentanil was assessed by the primary endpoint of
time from starting the study drug until time of extubation. The
safety profile of remifentanil was assessed by monitoring
haemodynamic parameters and recording adverse events
throughout the study period.
Materials and methods
This study was a randomised, open-label, multicentre, parallel-
group study comparing the safety and efficacy of an analgesia-
based regime using remifentanil with a conventional hypnotic-
based regime in critically ill patients requiring mechanical ven-
tilation for 3 to 10 days. The study was conducted in accord-
ance with good clinical practice and within the guidelines set
out in the Declaration of Helsinki. Informed consent/assent
was obtained from all patients or their representatives. After
approval from local and national ethics committees, 105
patients from 15 centres in 10 countries were recruited.
Patients were randomised in a 1:1 ratio to receive either a
remifentanil-based regime or a comparator hypnotic-based
regime using midazolam with either morphine or fentanyl for
analgesia.
Inclusion and exclusion criteria
The target population were those patients requiring long-term
mechanical ventilation for medical reasons. Post-surgical
patients requiring extended mechanical ventilation as a result
of post-surgical complications were also included. Patients
were eligible if they were more than 18 years old, had been
admitted to the intensive care unit (ICU) within the previous 30
hours, were expected to require mechanical ventilation for
longer than 96 hours and required analgesia and sedation.
Females were eligible to enter the study if they were of non-
childbearing potential or had a negative pregnancy test at
screening and agreed not to fall pregnant for 12 days after
stopping the study drug.
Patients were excluded from the study if their medical condi-
tion prevented assessment of depth of sedation, if it required
the frequent down-titration of analgesics/sedatives for assess-
ment, if it was likely to require surgery or tracheostomy during
the treatment period, if it required neuromuscular blocking
drugs by infusion, if it required epidural blockade, if it required
sedatives or anaesthetic agents other than study drugs speci-
fied in the treatment period, or if there was a contraindication
to the use of remifentanil, morphine, fentanyl or midazolam.
Other exclusions were sensitivity to the drugs or class of drugs
specified in the study, a history of alcohol or drug abuse, a
concurrent or previous entry into this or other investigational
drug studies within 30 days, or pregnancy or lactation. Proto-
col-specified treatment regimes had to be appropriate for the
management of the patients. After 30 patients had entered the
study, a protocol amendment allowed the inclusion of patients
who had been receiving mechanical ventilation for up to 30
hours irrespective of the time in the ICU, allowed the inclusion
of patients requiring surgery of less than 6 hours' duration dur-
ing the treatment period and reduced the required duration of
mechanical ventilation from 96 to 72 hours.
Study period
The study was divided into four periods: screening, treatment,
post-treatment and follow-up.Available online http://ccforum.com/content/9/3/R200
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Screening period
The screening period was from ICU admission to the start of
the study drug and included the time for considering eligibility,
obtaining consent/assent, randomisation and assessment of
the patient's SAPS II score. Baseline demographics, physio-
logical variables, Sedation–Agitation Scale (SAS) score and
pain intensity (PI) score were also assessed during this time.
The SAS is a seven-point scoring system, and a SAS score of
3 or 4 was defined as optimal sedation in this study (see Addi-
tional file 1, [18]). The PI score is a six-point score where 1 or
2 represents no pain or mild pain (see Additional file 2). Base-
line liver function tests and creatinine clearance were also
measured.
Treatment period
The treatment period was from the start of the study drug to
permanent discontinuation of the study drug, or after 10 days
of administration, or death, whichever was the sooner. SAS,
PI, heart rate (HR) and mean arterial pressure (MAP) were
continuously monitored throughout the treatment period and
were recorded at the time of each bolus dose and/or change
in infusion rate of any of the study drugs. These parameters
were recorded again when optimal sedation and pain control
had been established or re-established. These variables were
also recorded at least every 8 hours in the event of no change
in study drug. Study drugs and amount administered were also
recorded during the treatment period. Liver function tests and
creatinine clearance were assessed daily. Before the start of
administration of the study drugs the existing sedative/analge-
sic regime was discontinued. Patients were then sedated to an
optimal SAS and PI score by a remifentanil-based regime or a
hypnotic-based regime.
Remifentanil-based regime
The remifentanil infusion was started at 6 to 9 µg kg-1 h-1 (0.1
to 0.15 µg kg-1 min-1). The remifentanil infusion was titrated in
1.5 µg kg-1 h-1 (0.025 µg kg-1 min-1) increments at 5 to 10 min
intervals to achieve an optimum level of sedation/analgesia
based on clinical judgement. Bolus doses of remifentanil were
not permitted. Once the remifentanil infusion reached a rate of
12 µg kg-1 h-1 (0.2 µg kg-1 min-1), boluses of midazolam (not
more than 2 mg) could be used if required after clinical assess-
ment. Remifentanil was not used as the sole agent for sedation
at infusion rates greater than 18 µg kg-1 h-1 (0.3 µg kg-1 min-1).
Above this rate, midazolam boluses were used. Further
increases in the remifentanil rate were allowed for the treat-
ment of pain and in anticipation of short stimulating proce-
dures, up to a maximum rate of 45 µg kg-1 h-1 (0.75 µg kg-1 min-
1). The remifentanil dosing regime is depicted in Fig.
1[5,10,11].
Hypnotic-based regime
Midazolam was used by infusion and/or boluses as the seda-
tive agent, and was titrated to an optimum level of sedation
based on clinical judgement and in accordance with standard
clinical protocols. Either morphine or fentanyl was used as the
analgesic agent, titrated to obtain adequate pain control. The
initial dose and subsequent adjustments of sedative and anal-
gesic agents were at the investigators' discretion and in
accordance with routine clinical practice to obtain an optimum
SAS and PI score.
Weaning and extubation
The decision to begin the weaning process was based on clin-
ical judgement and was defined as the time point at which the
investigator first adjusted the study drug infusion rate or
decided not to give any more boluses of the study drugs so as
to encourage spontaneous respiration with the result of
Figure 1
The dosing algorithm The dosing algorithm.
Level of sedation
Increase Required
Decrease Required
Remifentanil <12 µgk g –1h–1
Remifentanil ≥18 µgk g –1h–1
Remifentanil ≥12 µgk g –1h–1
Increase remifentanil by 1.5 µgk g –1h–1
Decrease remifentanil
Decrease or discontinue midazolam if used,
decrease remifentanil if midazolam not used
Decrease or discontinue midazolam
Remifentanil <12 µgk g –1h–1
Remifentanil ≥18 µgk g –1h–1
Remifentanil ≥12 µgk g –1h–1
Increase remifentanil or give bolus
midazolam (≤2m g )
Give bolus midazolam (≤2m g )Critical Care    Vol 9 No 3    Breen et al.
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extubating the patient. For those patients extubated within 10
days, the study drugs were down-titrated in accordance with
clinical judgement until a decision was made to extubate the
patient. For patients in the comparator hypnotic-based
treatment group this was performed in accordance with rou-
tine clinical practice at the investigational site. As a guide, for
patients in the remifentanil group who were eligible for extuba-
tion, the remifentanil infusion was decreased to 6 µg kg-1 h-1
(0.1 µg kg-1 min-1) either immediately or in increments at the
investigator's discretion, and no further midazolam boluses
were given. Remifentanil was discontinued after extubation
and, if necessary, suitable alternative methods of pain relief
were instituted.
For patients not extubated within 10 days, the study drugs
were discontinued in both groups and the time to offset of
pharmacodynamic effects was recorded. As soon as there
was a demonstrable change in haemodynamic variables, SAS
score or PI score, alternative sedation and analgesic regimes
were instituted as soon as clinically indicated.
Post-treatment period
The post-treatment period was from the end of the treatment
period until 24 hours later. MAP, HR, SAS and PI were
recorded at 15 min intervals for the first 2 hours, hourly for the
next 4 hours then 6-hourly until the end of the post-treatment
period.
Follow-up period
The follow-up period was from the end of the post-treatment
period until 6 days later.
Study endpoints
Efficacy
The primary endpoint was the time from the start of study drug
to extubation. Secondary endpoints were the time from start of
study drug until start of weaning, the time from start of weaning
until extubation, the time from start of study drug to ICU dis-
charge, descriptive PI and SAS during the treatment and post-
treatment periods, total exposure to study drugs and concom-
itant sedative requirements.
Safety
The safety endpoints were the offset of pharmacodynamic
effects of study drugs after permanent discontinuation,
haemodynamic effects, clinical adverse events and the
requirement for re-intubation. Haemodynamic variables were
monitored continuously throughout the study and recorded at
the times stated above. Adverse events were recorded from
the start of the study drug until the end of the post-treatment
period. Serious adverse events were defined as adverse
events that resulted in any of the following outcomes: death,
life-threatening event, prolongation of hospitalisation, or a dis-
ability or incapacity. Important medical events that did not
result in death or were not life-threatening were considered
serious adverse events when, on the basis of appropriate med-
ical judgement, they jeopardised the patient and required med-
ical or surgical intervention to prevent one of the outcomes
listed above. In addition, serious adverse events possibly
attributable to study medication were recorded throughout the
6-day follow-up period.
Statistical analysis
The time to event endpoints were analysed with the general-
ised Wilcoxon test with a two-sided α  level of 5% judged to
Table 1
Patient characteristics and baseline clinical assessments
Characteristic Remifentanil Comparator
Number of patients treated 57 48
Medical (%)/post-surgical (%) 49 (88)/7 (13) 44 (92)/4 (8)
Emergency (%)/elective (%) 27 (84)/5 (16), n = 32 21 (91)/2 (9), n = 23
Age (years) 52.2 ± 18.4 57.3 ± 18.1
Male (%)/female (%) 39 (68)/18 (32) 32 (67)/16 (33)
Height (cm) 171.2 ± 9.7 169.0 ± 7.9
Weight (kg) 78.6 ± 13.41 76.3 ± 15.50
SAPS II on admission 43.0 ± 15.6 43.3 ± 11.2
MAP (mmHg)a 88.8 ± 16.5 88.9 ± 14.8
Heart rate (b.p.m.)a 98.9 ± 20.1 95.9 ± 15.5
SAS scorea 3.3 ± 1.3 3.3 ± 1.4
PI scorea 2.0 ± 1.2 2.1 ± 1.1
aBaseline values. Where errors are given, results are means± SD. MAP, mean arterial pressure; PI, pain intensity; SAS, Sedation–Agitation Scale.Available online http://ccforum.com/content/9/3/R200
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indicate a statistically significant difference between the treat-
ment groups. The data for patients who did not experience the
event were censored in accordance with predetermined rules.
The results of these analyses were summarised by using 75th
centiles, difference between 75th centiles and its 95% confi-
dence interval because too few patients achieved each event
to allow estimates based on median times to be determined
with any precision. The confidence intervals were calculated
with methods described by Collett [19].
The percentage time of optimal analgesia/sedation was calcu-
lated and summarised by the median in each treatment group
and the median of all possible differences between the groups
and the 95% confidence interval around that difference to give
the best estimate of median difference. Treatments were com-
pared by using the Wilcoxon rank sum test.
With the exception of the incidence of re-intubation, no formal
statistical analyses were performed on the demographic,
baseline or safety data. These data were summarised either by
Table 2
Study endpoints
Characteristic Remifentanil (n = 57) Comparator (n = 48) P
Number (%) of patients extubated 29 (51%) 16 (33%)
Time from start of study drugs to weaning (h) 83.0 98.0 0.523
Difference (95% CI) -15.0 (-61.8 to 31.8)
Time from start of study drugs to extubation(h) 94.0 147.5 0.033
Difference (95% CI) -53.5 (-111.4 to 4.4)
Time from weaning time until extubation (h) 0.9 27.5 <0.001
Difference (95% CI) -26.6 (-40.8 to -12.4)
Time from start of study drugs until ICU discharge (h) 187.3 209.8 0.326
Difference (95% CI) -22.5 (-201.5 to 156.5)
Point estimates are 75th centiles. CI, confidence interval.
Table 3
Adverse event profile
Characteristic Number of patients (%)
Remifentanil (n = 57) Comparator (n = 48)
Any adverse event 19 (33) 16 (33)
Any drug-related adverse event 6 (11) 4 (8)
Any serious adverse event 7 (12) 6 (13)
Any drug-related serious adverse event 0 (0) 1 (2)
Premature discontinuation from the study 12 (21) 10 (21)
Deaths 7 (13) 5 (10)
Re-intubated within 10 daysa 7 (25) 2 (12)
Most commonly occurring adverse events (≥  5%)
Hypotension 3 (5) 4 (8)
Atrial fibrillation 4 (7) 2 (4)
Vomiting 3 (5) 0 (0)
Septic shock 0 (0) 3 (6)
aP value for continuity-corrected χ 2. 95% confidence interval -4 to 23. P = 0.193. Time to re-intubation ranged from 2 h to 3 days after 
stopping remifentanil, and 7 hours to 3 days after stopping comparator agent.Critical Care    Vol 9 No 3    Breen et al.
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means and standard deviations (SD) or by frequency tables as
appropriate to the data.
Results
Fifty-seven patients were randomised to receive remifentanil
and 48 patients to receive comparator. Of the comparator
group, 62% (n = 30) received midazolam with fentanyl, 15%
(n = 7) received midazolam with morphine and 23% (n = 11)
received midazolam alone.
Patient demographics and baseline characteristics are shown
in Table 1. The two treatment groups were well matched in
terms of patient characteristics and baseline clinical assess-
ments. The time from ICU entry to the start of study medication
was slightly longer in the remifentanil group (remifentanil,
mean 23.6 hours, median 14.5; comparator, mean 18.9 hours,
median 16.9).
Efficacy
Efficacy endpoints are shown in Table 2. Fewer than 50% of
patients were extubated during the 10-day treatment period
(45 of 105). The 75th centile has been reported for the effi-
cacy endpoints. This analysis records the time at which 25%
of all patients reached the assessment points. There was no
difference in the time to the start of the weaning process.
There was a statistical and clinically significant difference
between the two groups in the study's primary endpoint of
time of starting the drug to extubation. A Kaplan–Meier plot
analysing the duration of mechanical ventilation is shown in
Fig. 2. The time difference was 53.5 hours, being shorter in the
remifentanil group (P = 0.033). The time from the start of the
weaning process to extubation was also significantly different
at 26.6 hours, also in favour of remifentanil (P < 0.001).
The median percentage time of optimal analgesia/sedation
was comparable for both groups (remifentanil 96.9%, compa-
rator 97.8%, median difference -0.3, 95% confidence interval
There were 16 patients in each group who survived to 10 days
but were not extubated, for whom the time to offset of pharma-
codynamic effects on discontinuing the study drugs was
assessed on 15 patients receiving remifentanil and 14
patients receiving comparator. This was found to be clinically
and significantly faster in the remifentanil group (Fig. 3).
Safety
The incidence of adverse events and the most commonly
occurring adverse events (5% or more) is illustrated in Table
3. The profile was similar for the two groups. Liver function
tests and creatinine clearance levels were comparable in both
groups at baseline and throughout the treatment period. One
drug-related serious adverse event was reported. This patient
was randomised to receive midazolam and fentanyl. At 1 day
after starting study medication the patient developed severe
hypotension, which was considered life threatening. There
were no reports of muscle rigidity. Comparable MAP and HR
values were observed during the post-treatment period.
Exposure to study drugs
The mean total duration, dose and weighted mean infusion
rates of study opioids for all the patients treated in this study
are illustrated in Table 4. Patients in the remifentanil group
received a longer duration of opioid infusion. Of the patients
treated with remifentanil, 26% (15 of 57) did not receive any
midazolam during the study. The remaining patients received
1 to 100 boluses during the treatment period. Figure 4 illus-
trates the mean total midazolam dose in patients receiving opi-
oids and no opioids. There was nearly a ninefold difference in
mean total midazolam requirements in the fentanyl group com-
pared with the remifentanil group, and a fourfold difference in
the morphine group compared with the remifentanil group.
Figure 2
Kaplan–Meier survival plot of time to extubation (days) Kaplan–Meier survival plot of time to extubation (days).
0
.
0
0
0
.
2
0
0
.
4
0
0
.
6
0
0
.
8
0
1
.
0
0
0 1 2 3 4 5 6 7 8 9 10
Remifentanil (n =5 7 )
Comparator (n =4 8 )
S
u
r
v
i
v
a
l
F
u
n
c
t
i
o
n
Time (days) to extubation
Figure 3
Median time to offset of effects as measured by the time to therapeutic  intervention Median time to offset of effects as measured by the time to therapeutic 
intervention.
1.167
0.25
(P < 0.001)
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Remifentanil Comparator
T
i
m
e
(
h
)
12Available online http://ccforum.com/content/9/3/R200
R206
Figure 5 shows the weighted mean infusion rate of opioid by
day. Remifentanil infusion requirements rose within the first
few days then reached a plateau. Figure 6 represents the
mean total daily midazolam requirements in combination with
each opioid used. The midazolam requirements with remifen-
tanil were the least and did not change significantly with time.
SAS and PI scores during the post-treatment period
The SAS and PI scores were the same in the remifentanil and
comparator groups throughout the post-treatment period.
There was no variation over the 24-hour period in either group.
The variation in the mean SAS over 24 hours was 3.1 to 3.3
for remifentanil group and 2.7 to 3.0 in the comparator group.
The variation in the mean PI over 24 hours was 1.5 to 1.6 for
the remifentanil group and 1.5 to 1.7 for the comparator group.
Discussion
The technique of using remifentanil as the primary sedative
and analgesic, with the addition of traditional sedatives such
as propofol or midazolam only if necessary, has been studied
in ICU patients for up to 3 days [5,11,17] and in neurosurgical
patients studied for up to 5 days, with good results [12]. Anec-
dotally, remifentanil has been used in the ICU population for
much longer periods [6]. This is the first study to look at the
use of remifentanil for prolonged infusions in ICU patients for
up to 10 days. The primary aim of the study was to compare
the safety of the techniques and the duration for which
patients were on mechanical ventilation.
Efficacy
The present study has clearly demonstrated a clinically and
statistically significant decrease in duration of mechanical ven-
tilation when using remifentanil-based analgesia and sedation.
The difference between remifentanil and the comparator
group was more than 2 days (53.5 hours). The time from start-
ing the weaning process to extubation was also significantly
different by more than 1 day (26.6 hours). Reducing the dura-
tion of mechanical ventilation by a matter of days will poten-
tially help to reduce the complications associated with
prolonged intubation and ventilation. These differences cannot
be explained by differing eligibilities to start the weaning proc-
ess, because there was no difference between the times to
start the weaning process in either of the two study groups.
The SAS and PI scores were the same in both groups from
baseline through the treatment period and to the end of the
post-treatment period. The difference therefore cannot be
explained by different sedation levels between the groups.
There are difficulties of comparing extubation times between
sedative regimes in an ICU study. Studies have looked at
extubation times after anaesthesia, comparing various drugs
[20,21]. The time frame for these studies is much shorter, and
the times of decisions to stop study drug(s) and extubate
patients are much easier to define. It is possible that a critically
ill patient will undergo several increases and decreases in sed-
ative and analgesic agents before the decision is made to
wean and extubate. It is possible that patients will have been
on no drug for some time. Given these points, the difference in
the primary endpoint of the study in a small group of patients
is remarkable.
There was a trend towards a shorter ICU stay in the remifen-
tanil group by 1 day although this was not statistically
Table 4
Exposure to study drug for all patients treated
Parameter Remifentanil (n = 57) Fentanyl (n = 30) Morphine (n = 7)
Mean duration of infusion (h) 147.2 126.4 120.5
Mean total opioid dose 221,614 µg 20,702 µg 237.5 mg
Mean weighted mean opioid infusion rate(SD) 19.2a (12.2) µg kg-1 h-1 3.0 (3.35) µg kg-1 h-1 0.042 (0.028) mg kg-1 h-1
aEquivalent to 0.32 µg kg-1 min-1.
Figure 4
Mean total midazolam dose Mean total midazolam dose.
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significant. This may be because the numbers of patients who
were actually extubated within the study period were small and
the study was not sufficiently powered to detect the differ-
ence. Whereas discharge from an ICU setting is multifactorial
and often depends on factors not related to the medical con-
dition of the patient such as bed shortages on the ward and
the time of day. The trend in reduced duration of ICU stay is
supported by the work of Matthey and colleagues [22], who
showed that remifentanil supplemented with propofol signifi-
cantly reduced the time on mechanical ventilation and allowed
earlier discharge from the ICU than an analgesia-based seda-
tion with fentanyl/midazolam. In another study comparing
Figure 5
Mean weighted mean opioid infusion over time Mean weighted mean opioid infusion over time.
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remifentanil/midazolam with morphine/midazolam in a similar
way to this study, there was a significant difference between
the extubation times and ICU discharge times between the
two groups [17]. However, the duration of mechanical ventila-
tion was relatively short.
The context-sensitive half-time of remifentanil is constant and
independent of duration of drug administration when adminis-
tered for up to 6 hours [3], but does this situation change
when remifentanil is given for days rather than hours? One
study looked at the pharmacodynamic offset of remifentanil at
various time points over 3 days in ICU patients and found that
the offset time was constant over this period [5]. In the present
study there was no evidence of accumulation of remifentanil
over time. Of the patients who were not extubated within 10
days, on discontinuing the remifentanil infusion the mean time
to offset of pharmacodynamic effect was only 15 min and was
identical to that obtained in the study above [5]. A recent
paper has shown that if sedation in ICU patients was stopped
on a daily basis, it considerably reduced the duration of
mechanical ventilation and ICU stay [23]. However, these
patients were heavily sedated. This study and the above study
demonstrates that if patients are sedated to an optimum SAS
and PI score with remifentanil, then despite the duration of
sedation the pharmacodynamic offset time is about 15 min,
making a daily 'wake-up call' unnecessary for the reasons of
decreasing the amount of total sedation and aiding extubation
and ICU discharge.
The duration for which patients had an optimum SAS and PI
score was the same in each group and was more than 96% of
the duration for which patients were receiving treatment. This
is to be expected, because the aim of the study was to titrate
the analgesic/sedative regimes to achieve target SAS and PI
scores that were optimal. Thus, the only effect on the primary
endpoint was the drugs used and not the variation in sedation/
analgesic levels.
Safety
The reported incidence of adverse effects in this study was the
same in the remifentanil and comparator groups. The inci-
dence was also similar to those in other studies looking at the
safety of remifentanil and comparator agents in ICU patients
[5,11,12]. The adverse events were also in keeping with
events that one would expect in an ICU population. The only
serious adverse event that was reported as drug-related
occurred in the comparator group. This was of severe life-
threatening hypotension. Deaths were the same in each group
and at the expected rate for an ICU population. No deaths
were reported as a result of the study drug. There were no
reports of muscle rigidity or of prolonged µ-opioid effects as a
consequence of using remifentanil. There was no statistical
difference in the incidence of re-intubation between the two
treatment groups.
There was no evidence of adverse SAS or PI scores on dis-
continuing the remifentanil. The mean SAS and PI scores were
the same in each group and stable for the 24-hour post-treat-
ment period. Investigators were able to use the regime of their
choice to optimise PI and SAS after extubation, in line with rou-
tine clinical practice. There was no evidence that remifentanil
sensitised opioid receptors or that the rapid offset of pharma-
codynamic effects of remifentanil caused problems with con-
trol of pain after extubation.
Exposure to study drugs
In the comparator group the weighted mean infusion rates of
fentanyl and morphine were relatively constant throughout the
study. The large increase in the morphine requirements on
days 8 and 9 represented one patient only.
The weighted mean remifentanil infusion rate to maintain opti-
mum SAS and PI scores was 19.2 µg kg-1 h-1 (0.32 µg kg-1
min-1) (Table 4). This is slightly higher than reported previously,
but well within the infusion rates recommended [5,11]. The
remifentanil use remained relatively constant throughout the
study, and generally the remifentanil was given for longer than
the other opioids (Fig. 5, Table 4).
The midazolam requirements were considerably reduced in
the remifentanil group and were relatively constant throughout
the treatment period (Figs 4 and 6). This is a reflection of the
hypnotic-agent-sparing effects of remifentanil and the ease
with which the infusion can be titrated to obtain optimum
patient comfort [11,17].
Figure 6
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In contrast, the mean total daily requirements for midazolam in
the comparator group varied considerably throughout the
study period to maintain an optimal SAS for 97% of the time.
There was an up to 10-fold difference in mean daily midazolam
requirements in the fentanyl subgroup (226 mg on day 4; 26
mg on day 10) and a sevenfold difference in the morphine sub-
group (189.6 mg on day 5; 28.4 mg on day 10). This accounts
for the difference in mean total midazolam requirements
between the groups. The requirements for midazolam peaked
between days 3 and 5 in the comparator groups, and then
tailed off (Fig. 6). The above observations are a reflection of
two factors. First, midazolam was used as the primary hypnotic
agent in the comparator group and it was therefore adjusted
first. Second, although the opioid infusion rates remained rel-
atively constant, as the study progressed, opioid and mida-
zolam accumulation occurred. The accumulation, with large
body stores of these drugs, contributed to the sedation in
these patients. Therefore the requirement for midazolam
administration to maintain a constant SAS and PI score tailed
off after a certain period. The context-sensitive half-time of the
comparator agents is known to increase with time, and the
comparator agent's elimination is organ dependent [1,24].
There was no clinical evidence of the development of toler-
ance to remifentanil as demonstrated by escalating remifen-
tanil requirements or post-infusion opioid requirements. The
weighted mean infusion rate of remifentanil increased slightly
until day 3, and was then constant until day 10. The SAS and
PI scores at the start and throughout the post-treatment period
were the same as in the comparator, and were constant.
There was a group of patients who received only midazolam to
provide patient comfort during their stay in the ICU. This
occurred at one hospital where this was the preferred practice
for the treatment of medical patients without injuries and
reflected normal clinical practice at that site.
The present study compares two different sedation tech-
niques. One technique used the analgesic component of the
regime as the main variant for sedation (remifentanil). The
other used the hypnotic component as the main variant for
sedation (midazolam). Although this second group gave rise to
three subgroups because either fentanyl, morphine or no anal-
gesic was used, this was unimportant. The main aim was to
compare the remifentanil regime with common 'standard prac-
tice' for sedation in ICU patients. It would not have been rep-
resentative of clinical practice to compare two opioids in an
analgesia-based regime: the commonly used opioids cannot
be used in this way because of the real risk of accumulation.
The present study clearly demonstrates that the remifentanil-
based regime is superior in terms of reduced time for weaning
and, more importantly, reduced duration of mechanical
ventilation.
Conclusion
The use of remifentanil in an analgesic-based sedative regime
in critically ill patients significantly decreases the duration of
mechanical ventilation and of weaning. It is sedative sparing
and has a very rapid offset even after a 10-day infusion, with
no evidence of accumulation. Remifentanil was well tolerated
throughout a 10-day infusion. The adverse event profile was
similar in remifentanil-based and hypnotic-based regimes. No
adverse events relating to muscle rigidity or prolonged µ-opi-
oid effects were reported. The SAS and PI scores after treat-
ment were comparable. There was no evidence of the
development of tolerance to remifentanil and there was no dif-
ficulty in maintaining optimal SAS and PI scores after treat-
ment with remifentanil with the use of standard treatment
regimes.
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Key messages
•  The use of remifentanil-based analgesia and sedation 
significantly reduced the duration of mechanical 
ventilation.
•  Weaning patients from mechanical ventilation can be 
achieved significantly faster with remifentanil-based 
analgesia and sedation.
•  Remifentanil has a very rapid offset even after a 10-day 
infusion with no evidence of accumulation.
•  There was no evidence of the development of tolerance 
to remifentanil and there was no increase in opioid 
requirements after treatment with remifentanil, even 
after prolonged use.
• A  remifentanil-based  analgesia and sedation regimen is 
well tolerated when used for up to 10 days in critically ill 
patients requiring mechanical ventilation and has a 
safety profile similar to that observed for hypnotic-based 
sedation.Available online http://ccforum.com/content/9/3/R200
R210
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